Antiretroviral switch studies do matter

Lancet HIV. 2018 Oct;5(10):e546. doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8.

Authors

Eric S Daar¹, Peter Ruane², Edwin DeJesus³, Hans-Jürgen Stellbrink⁴, Jean-Michel Molina⁵

Affiliations

¹ Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. Electronic address: edaar@labiomed.org.
² Ruane Clinical Research Group, Los Angeles, CA, USA.
³ Orlando Immunology Center, Orlando, FL, USA.
⁴ Infectious Disease Medical Center, Hamburg, Germany.
⁵ Department of Infectious Diseases, Saint-Louis Hospital, University of Paris Diderot, Paris, France.

PMID: 30319119
DOI: 10.1016/S2352-3018(18)30259-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Amides
Anti-HIV Agents
Anti-Retroviral Agents
HIV Infections*
Heterocyclic Compounds, 3-Ring
Heterocyclic Compounds, 4 or More Rings
Humans
Piperazines
Pyridones

Substances

Amides
Anti-HIV Agents
Anti-Retroviral Agents
Heterocyclic Compounds, 3-Ring
Heterocyclic Compounds, 4 or More Rings
Piperazines
Pyridones
bictegravir